Pirfenidone

證據等級: L5

預測適應症: 10 個

PIRFENIDONE: From Idiopathic Pulmonary Fibrosis to Extracutaneous Mastocytoma

One-Sentence Summary

Pirfenidone is an antifibrotic agent whose established pharmacology (inhibition of TGF-β1 and PDGF signaling, reducing fibroblast proliferation and collagen synthesis) underlies its approval for idiopathic pulmonary fibrosis. The TxGNN model predicts it may be effective for Extracutaneous Mastocytoma, but no clinical trials and no publications currently support this specific direction — this is a model-only prediction with a mechanistically weak rationale.

Quick Overview

Item	Content
Original Indication	Idiopathic Pulmonary Fibrosis (per literature reference in evidence pack; no structured license record available)
Predicted New Indication	Extracutaneous Mastocytoma
TxGNN Prediction Score	99.71%
Evidence Level	L5
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Structured mechanism-of-action data is not available for pirfenidone in this evidence pack. However, literature captured elsewhere in the pack (PMID 29702057) describes its known pharmacology: pirfenidone inhibits TGF-β1 and platelet-derived growth factor signaling, leading to decreased fibroblast proliferation and collagen synthesis. This antifibrotic mechanism is the basis of its approval for idiopathic pulmonary fibrosis.

Extracutaneous mastocytoma, by contrast, is a mast cell neoplasm whose pathogenesis is driven primarily by KIT mutations and mast cell hyperproliferation — a pathway that does not overlap with pirfenidone’s TGF-β1/collagen-synthesis mechanism. The evidence pack’s own rationale for this prediction explicitly flags this gap: “TxGNN’s high score reflects only knowledge-graph embedding similarity; pirfenidone’s known action of inhibiting TGF-β1-mediated fibroblast proliferation/collagen synthesis and anti-inflammatory effects has no direct biological connection to the pathogenic mechanism of mast cell tumors (KIT mutation, mast cell proliferation) — the mechanistic link is weak.”

In other words, this prediction currently rests on graph-embedding similarity rather than any plausible or demonstrated biological pathway, and should be treated as a low-confidence hypothesis rather than a repurposing lead.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

Pirfenidone has no license records in this evidence pack (total_licenses: 0, market status: Not Marketed). No authorization or product information is available to report.

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA label warnings/contraindications are recorded as a Blocking data gap (DG001) in this evidence pack — this must be resolved before any S1 safety review can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction for extracutaneous mastocytoma is supported only by a TxGNN embedding score (L5, model prediction only) — there are zero clinical trials and zero publications, and the drug’s known antifibrotic mechanism does not plausibly connect to the KIT-mutation-driven pathology of this mast cell tumor.

To proceed, the following is needed:

Resolve DG001 (Blocking): TFDA/manufacturer label warnings and contraindications
Resolve DG002 (High): confirm pirfenidone’s mechanism of action via DrugBank or primary literature
In vitro/preclinical evidence testing pirfenidone activity in KIT-mutant mast cell models
If mechanistic plausibility cannot be established, deprioritize this candidate in favor of higher-evidence predictions in the same batch (e.g., the fibroblastic neoplasm candidate, which has L3/S1 evidence but also carries an unresolved safety signal — sarcoma occurrence after pirfenidone use, PMID 29702057 — that should be investigated in parallel)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.